Trial NCT00616122

View at ClinicalTrials.gov 
Org. Study IDs: 057519
Secondary IDs: NCI-2011-01275

Last trial update was posted on 2020-01-13

MeSH Interventions

Cyclophosphamide Methotrexate Sunitinib

MeSH Conditions

Breast Neoplasms

Other Conditions

Breast Cancer

Stopping Reasons

Risk to benefit ratio not acceptable

Limitations And Caveats

Based on published literature indicating significant toxicity and low response rate for combination sunitinib in the treatment of advanced breast cancer, the PI and Breast Oncology Site Committee closed enrollment after accrual of 32 participants.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID